NorthStar Medical Radioisotopes has entered into a collaboration deal with YAP Therapeutics, to develop and produce radiopharmaceuticals aimed at treating cancer and other chronic diseases.

NorthStar is involved in the development, production, and commercialization of radiopharmaceuticals for therapeutic applications and medical imaging. YAP Therapeutics, a Fjord Ventures company, utilizes its advanced biologic and regenerative medicine technology platforms to develop treatments for chronic diseases.

Within this collaboration, NorthStar will support the development of YAP Therapeutics' biologic products by supplying the radioisotope non-carrier added actinium-225 (n.c.a. Ac-225) and providing access to its radiopharmaceutical contract development and manufacturing (CDMO) services.

NorthStar will also prepare clinical trial-ready doses of YAP Therapeutics' investigational medicines. Additionally, upon regulatory approval, NorthStar may manufacture and supply radionuclides for YAP Therapeutics' commercial use.

“NorthStar leads in medical radioisotope development and production. This agreement furthers our goal to deliver radiopharmaceuticals to patients. We are excited to partner with YAP Therapeutics, merging our technology with their biologics to target specific therapies. Our ability to provide key radioisotopes like Ac-225 and CDMO capabilities offers substantial support to YAP Therapeutics,” said Frank Scholz, President and Chief Executive Officer of NorthStar.

"We are thrilled about partnering with NorthStar to improve cancer treatment. Their radiopharmaceutical expertise complements our biologics development. This partnership offers the potential to expand our rich pipeline with leading radioisotope technology," said Olav Bergheim, Founder and Chairman of YAP Therapeutics.